Therapeutic faecal microbiota transplantation: current status and future developments.
Therapeutic faecal microbiota transplantation: current status and future developments.
复制标题
DOI：
10.1097/mog.0000000000000027
复制
发表时间：
2014-01
影响因子：
2.5
通讯作者：
Paramsothy S
中科院分区：
文献类型：
--
作者：
Borody TJ;Brandt LJ;Paramsothy S
粪便微生物区系移植(FMT)在过去的一年中经历了戏剧性的进展，并随着对胃肠道微生物区系(GiMb)的了解不断发展。本文综述了FMT的治疗进展和最新的FMT疗法，并介绍了FMT疗法在其他胃肠道和肠外疾病中的应用潜力。现在已知GiMb在许多疾病的发病机制中起着核心作用。FMT在治疗艰难梭菌感染(CDI)方面的成功已经得到证实，在其他胃肠道疾病中的初步发现也是有希望的。来自500多个CDI病例的公布数据表明，FMT通常耐受性良好，副作用最小。FMT的商业潜力正在探索中，有几种产品正在开发中，包括冷冻GiMb提取物，它已被证明对治疗复发的CDI非常有效。这类产品很可能在未来几年变得更容易获得，并彻底改变GiMb的可用性和交付方法。最近的文献明确支持使用FMT治疗复发性CDI。目前正在进行试验，以确定FMT在其他情况下的治疗潜力，特别是炎症性肠病。治疗性FMT是一个动态的领域，具有新的和新兴的适应症，以及最佳给药模式的持续发展。
Faecal microbiota transplantation (FMT) has undergone dramatic progression over the past year and continues to evolve as knowledge of the gastrointestinal microbiota (GiMb) develops. This review summarizes therapeutic advances in FMT, latest FMT therapies and presents the potential of FMT therapeutics in other gastrointestinal and extra-intestinal conditions. The GiMb is now known to have a central role in the pathogenesis of many diseases. The success of FMT in curing Clostridium difficile infection (CDI) is well established and preliminary findings in other gastrointestinal conditions are promising. Published data from over 500 CDI cases suggest that FMT is generally well tolerated with minimal side effects. The commercial potential of FMT is being explored with several products under development, including frozen GiMb extract, which has been shown highly effective in treating relapsing CDI. Such products will likely become more available in coming years and revolutionize the availability and method of delivery of GiMb. Recent literature unequivocally supports the use of FMT in treating relapsing CDI. Trials are underway to determine the therapeutic potential of FMT in other conditions, particularly inflammatory bowel disease. Therapeutic FMT is a dynamic field with new and emerging indications along with ongoing developments in optimal mode of administration.